Valemetostat Tosylate

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Adult T-cell Leukemia/Lymphoma

Conditions

Adult T-cell Leukemia/Lymphoma

Trial Timeline

Nov 21, 2019 → Oct 27, 2024

NCT ID

NCT04102150

About Valemetostat Tosylate

Valemetostat Tosylate is a phase 2 stage product being developed by Daiichi Sankyo for Adult T-cell Leukemia/Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04102150. Target conditions include Adult T-cell Leukemia/Lymphoma.

What happened to similar drugs?

9 of 20 similar drugs in Adult T-cell Leukemia/Lymphoma were approved

Approved (9) Terminated (2) Active (11)

✅BenralizumabAstraZenecaApproved

✅FluMist + inactivated influenza vaccineAstraZenecaApproved

✅Saizen® solution for injection (referred as Saizen®)MerckApproved

✅Tacrolimus/Sirolimus + Tacrolimus/MMF + Neoral/SirolimusRocheApproved

✅Aztreonam lysineGilead SciencesApproved

✅maraviroc + Raltegravir + Darunavir/ritonavirPfizerApproved

✅SabrilLundbeckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07303387	Phase 2	Recruiting	Feb 28, 2026	Feb 28, 2032	Solid Tumor Malignancies
NCT04842877	Phase 2	Active	Jun 11, 2021	Oct 1, 2026	Lymphoma, B-Cell
NCT04703192	Phase 2	Active	Jun 3, 2021	Feb 19, 2027	Relapsed/Refractory Peripheral T-Cell Lymphoma
NCT04102150	Phase 2	Completed	Nov 21, 2019	Oct 27, 2024	Adult T-cell Leukemia/Lymphoma

Competing Products

20 competing products in Adult T-cell Leukemia/Lymphoma

See all competitors

Product	Company	Stage	Hype Score
BBP-398 + sotorasib	BridgeBio Pharma	Phase 1	18
Daridorexant + Placebo	Idorsia	Phase 1	23
SON-1010 (IL12-FHAB)	Sonnet BioTherapeutics	Phase 1	23
Somatropin	Eli Lilly	Phase 3	40
agenT-797	MiNK Therapeutics	Phase 1	19
Pegilodecakin	Eli Lilly	Phase 1	29
eFT226 + Sotorasib + Fulvestrant + Abemaciclib + Trastuzumab	eFFECTOR Therapeutics	Phase 1/2	29
Lazertinib(G001) + Lazertinib(G002)	Yuhan	Phase 1	29
Patritumab deruxtecan	Daiichi Sankyo	Phase 2	27
DJ-927 + capecitabine	Daiichi Sankyo	Phase 1	29
Roxadustat	Astellas Pharma	Phase 1	29
ASP3325 + Placebo	Astellas Pharma	Phase 1	29
TRK-100STP	Astellas Pharma	Phase 1	29
Ensitrelvir	Shionogi	Phase 1	29
E6130 + Placebo	Eisai	Phase 1	29
E7389 + E7389 + E7389	Eisai	Phase 1	29
Eribulin Mesylate	Eisai	Phase 1	29
E2022 + E2022 + E2022 + E2022 + E2022	Eisai	Phase 1	29
Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride	Eisai	Phase 1	29
Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride	Eisai	Phase 1	29